Schizophrenia Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Schizophrenia stocks.

Schizophrenia Stocks Recent News

Date Stock Title
Nov 22 LLY Sanofi Plans to Change Hospital Drug-Discount Program
Nov 22 AZN Pharma Stock Roundup: EU Nod for PFE's Hympavzi, NVS Ups Sales View
Nov 22 BLRX BioLineRx Q3 2024 Earnings Preview
Nov 22 LLY VKTX Stock Loses Over $1B in a Month: How to Play the Stock?
Nov 22 LLY Investing in Pharma Stocks? Check These 3 Things First
Nov 22 BDRX Result of General Meeting
Nov 22 LLY Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry?
Nov 22 BLRX BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell
Nov 22 LLY Goldman Sachs: Eli Lilly and Company (LLY) Is A Top Growth Investor Stock
Nov 21 LLY The FDA Can’t Decide Whether Zepbound Is in Shortage. It’s Good News for Hims & Hers Stock.
Nov 21 LLY Eli Lilly Stock: Unexpected Developments (Rating Downgrade)
Nov 21 LLY Hims & Hers closes up 10% as Lilly tirzepatide compounding dispute resolution delayed
Nov 21 LLY Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs
Nov 21 AZN AstraZeneca's Andexxa Faces FDA Scrutiny Over Effectiveness, Safety Concerns
Nov 21 LLY Is Now a Good Time to Buy the Dip in Eli Lilly Stock?
Nov 21 AZN Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Nov 21 BLRX BioLineRx inks licensing deal, share purchase agreement
Nov 21 AZN We Think AstraZeneca's (LON:AZN) Healthy Earnings Might Be Conservative
Nov 21 BDRX Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic
Nov 21 BLRX BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.
Schizophrenia

Schizophrenia is a mental disorder characterized by abnormal behavior, strange speech and a decreased ability to understand reality. Other symptoms include false beliefs, unclear or confused thinking, hearing voices that do not exist, reduced social engagement and emotional expression and lack of motivation. People with schizophrenia often have additional mental health problems such as anxiety, depressive or substance-use disorders. Symptoms typically come on gradually, begin in young adulthood and in many cases never resolve.The causes of schizophrenia include environmental and genetic factors. Possible environmental factors include being raised in a city, cannabis use during adolescence, certain infections, the age of a person's parents, and poor nutrition during pregnancy. Genetic factors include a variety of common and rare genetic variants. Diagnosis is based on observed behavior, the person's reported experiences and reports of others familiar with the person. During diagnosis, a person's culture must also be taken into account. As of 2013, there is no objective test. Schizophrenia does not imply a "split personality" or dissociative identity disorder, conditions with which it is often confused in public perception.The mainstay of treatment is antipsychotic medication, along with counselling, job training and social rehabilitation. It is unclear whether typical or atypical antipsychotics are better. In those who do not improve with other antipsychotics, clozapine may be tried. In more serious situations where there is risk to self or others, involuntary hospitalization may be necessary, although hospital stays are now shorter and less frequent than they once were.About 0.3% to 0.7% of people are affected by schizophrenia during their lifetimes. In 2013, there were an estimated 23.6 million cases globally. Males are more often affected and on average experience more severe symptoms. About 20% of people eventually do well, and a few recover completely; about 50% have lifelong impairment. Social problems, such as long-term unemployment, poverty and homelessness, are common. The average life expectancy of people with the disorder is 10–25 years less than that of the general population. This is the result of increased physical health problems and a higher suicide rate (about 5%). In 2015, an estimated 17,000 people worldwide died from behavior related to, or caused by, schizophrenia.

Browse All Tags